VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis

被引:233
作者
Dong, JY
Grunstein, J
Tejada, M
Peale, F
Frantz, G
Liang, WC
Bai, W
Yu, LL
Kowalski, J
Liang, XH
Fuh, G
Gerber, HP
Ferrara, N
机构
[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA
关键词
angiogenesis; fibrosarcoma; PDGF; stroma; VEGF;
D O I
10.1038/sj.emboj.7600289
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We generated VEGF-null fibrosarcomas from VEGF-loxP mouse embryonic fibroblasts to investigate the mechanisms of tumor escape after VEGF inactivation. These cells were found to be tumorigenic and angiogenic in vivo in spite of the absence of tumor-derived VEGF. However, VEGF derived from host stroma was readily detected in the tumor mass and treatment with a newly developed anti-VEGF monoclonal antibody substantially inhibited tumor growth. The functional significance of stroma-derived VEGF indicates that the recruitment of stromal cells is critical for the angiogenic and tumorigenic properties of these cells. Here we identified PDGF AA as the major stromal fibroblast chemotactic factor produced by tumor cells, and demonstrated that disrupting the paracrine PDGFR alpha signaling between tumor cells and stromal fibroblasts by soluble PDGFR alpha-IgG significantly reduced tumor growth. Thus, PDGFR alpha signaling is required for the recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth. Our findings highlight a novel aspect of PDGFR alpha signaling in tumorigenesis.
引用
收藏
页码:2800 / 2810
页数:11
相关论文
共 67 条
[1]   Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors [J].
Abramsson, A ;
Lindblom, P ;
Betsholtz, C .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (08) :1142-1151
[2]   The role of the microenvironment and intercellular cross-talk in tumor angiogenesis [J].
Ahmad, SA ;
Jung, YD ;
Liu, WB ;
Reinmuth, N ;
Parikh, A ;
Stoeltzing, O ;
Fan, F ;
Ellis, LM .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (02) :105-112
[3]  
Barbera-Guillem E, 2002, CANCER RES, V62, P7042
[4]   COMPARISON OF BIOLOGICAL PROPERTIES AND TRANSFORMING POTENTIAL OF HUMAN PDGF-A AND PDGF-B CHAINS [J].
BECKMANN, MP ;
BETSHOLTZ, C ;
HELDIN, CH ;
WESTERMARK, B ;
DIMARCO, E ;
DIFIORE, PP ;
ROBBINS, KC ;
AARONSON, SA .
SCIENCE, 1988, 241 (4871) :1346-1349
[5]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[6]  
Berking C, 2001, CANCER RES, V61, P8306
[7]   STRUCTURAL AND FUNCTIONAL-ASPECTS OF PLATELET-DERIVED GROWTH-FACTOR AND ITS ROLE IN THE PATHOGENESIS OF GLIOBLASTOMA [J].
BETSHOLTZ, C ;
NISTER, M ;
RORSMAN, F ;
HELDIN, CH ;
WESTERMARK, B .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1989, 10 (01) :27-36
[8]  
Bhardwaj B, 1996, CLIN CANCER RES, V2, P773
[9]   Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice [J].
Blaskovich, MA ;
Lin, Q ;
Delarue, FL ;
Sun, J ;
Park, HS ;
Coppola, D ;
Hamilton, AD ;
Sebti, SM .
NATURE BIOTECHNOLOGY, 2000, 18 (10) :1065-1070
[10]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439